{"id":32736,"date":"2024-07-03T12:11:21","date_gmt":"2024-07-03T12:11:21","guid":{"rendered":"https:\/\/ibima.eu\/estudio-en-fase-ii-doble-ciego-y-controlado-con-placebo-de-setmelanotide-en-pacientes-con-defectos-geneticos-especificos-en-la-via-del-receptor-de-la-melanocortina-4-en-dos-etapas-preinclusion-abie\/"},"modified":"2024-07-03T12:11:21","modified_gmt":"2024-07-03T12:11:21","slug":"estudio-en-fase-ii-doble-ciego-y-controlado-con-placebo-de-setmelanotide-en-pacientes-con-defectos-geneticos-especificos-en-la-via-del-receptor-de-la-melanocortina-4-en-dos-etapas-preinclusion-abie","status":"publish","type":"post","link":"https:\/\/ibima.eu\/en\/estudio-en-fase-ii-doble-ciego-y-controlado-con-placebo-de-setmelanotide-en-pacientes-con-defectos-geneticos-especificos-en-la-via-del-receptor-de-la-melanocortina-4-en-dos-etapas-preinclusion-abie\/","title":{"rendered":"Estudio en fase II, doble ciego y controlado con placebo de setmelanotide en pacientes con defectos gen\u00e9ticos espec\u00edficos en la v\u00eda del receptor de la melanocortina 4, en dos etapas (preinclusi\u00f3n abierta seguida de retirada aleatorizada)"},"content":{"rendered":"
FRANCISCO JOS\u00c9 TINAHONES MADUE\u00d1O – ENSAYO CL\u00cdNICO CON MEDICAMENTOS – RHYTHM PHARMACEUTICALS, INC.<\/p>","protected":false},"excerpt":{"rendered":"
FRANCISCO JOS\u00c9 TINAHONES MADUE\u00d1O – ENSAYO CL\u00cdNICO CON MEDICAMENTOS – RHYTHM PHARMACEUTICALS, INC.<\/p>","protected":false},"author":2,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"_et_pb_use_builder":"","_et_pb_old_content":"","_et_gb_content_width":"","footnotes":""},"categories":[2263,2266],"tags":[],"acf":[],"yoast_head":"\n